fda warning letters compounded semaglutide telehealth 2025 warns providers over obesity drug marketing FDA Warns 30 Telehealth Companies

In a double-blind, placebo-controlled trial, participants were randomly assigned in a 1:1:1:1 ratio to receive once-weekly subcutaneous tirzepatide or placebo

[11] It is not known whether sermorelin can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity

10.18632/oncotarget.7814 190

showed improvement in lung function in COPD mice treated with the GLP-1 receptor agonist

Medullary thyroid cancer and C-cell hyperplasia remain a boxed warning for both medications based on animal studies, not human evidence

Moreover, patients using Lumigan may experience l ong-term psychological and social impacts due to unexpected changes in eye color